NEW YORK, NY / ACCESSWIRE / November 2, 2018 / U.S. markets rallied on Thursday, with the S&P 500 Index logging its first 3-day win streak in six weeks, as trade concerns between the U.S. and China continued to ease. The Dow Jones Industrial Average gained 1.06 percent to close at 25,380.74, while the S&P 500 Index increased 1.06 percent to close at 2,740.37. The Nasdaq Composite Index jumped 1.75 percent to close at 7,434.06.
“Equity markets were a sea of green yesterday, as risk appetite remained supported for another day. White House economic adviser Kudlow said that more tariffs on China are not ‘set in stone’, which may have boosted somewhat further market sentiment.” wrote Charalambos Pissouros,
RDI Initiates Coverage on:
Loxo Oncology, Inc.
Auris Medical Holding AG
Loxo Oncology's stock jumped 7.62% Thursday, to close the day at $164.30. The stock recorded a trading volume of 349,383 shares, which was above its three months average volume of 290,838 shares. In the last year, Loxo Oncology's shares have traded in a range of 71.45 - 208.95. The share price has gained 129.95% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $161.66 is below its 200-day moving average of $162.30. Shares of Loxo Oncology have fallen roughly 1.71 percent in the past month and are up 95.18 percent year-to-date.
Access RDI's Loxo Oncology, Inc. Research Report at:
On Thursday, shares of Auris Medical Holding recorded a trading volume of 15,189,297 shares, which was above the three months average volume of 6,115,500 shares. The stock ended the day 48.44% higher at $0.95. The share price has fallen 90% from its 52
Access RDI's Auris Medical Holding Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.